$2.08
2.72% today
Nasdaq, Apr 03, 06:42 pm CET
ISIN
US68620A1043
Symbol
ONVO
Sector
Industry

Organovo Holdings, Inc. Stock price

$2.14
-6.26 74.53% 1M
-3.56 62.46% 6M
-3.38 61.22% YTD
-10.22 82.69% 1Y
-41.06 95.05% 3Y
-59.30 96.52% 5Y
-890.66 99.76% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.09 4.04%
ISIN
US68620A1043
Symbol
ONVO
Sector
Industry

Key metrics

Market capitalization $3.64m
Enterprise Value $3.80m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 31.67
P/S ratio (TTM) P/S ratio 30.33
P/B ratio (TTM) P/B ratio 8.39
Revenue growth (TTM) Revenue growth -49.59%
Revenue (TTM) Revenue $120.00k
EBIT (operating result TTM) EBIT $-12.56m
Free Cash Flow (TTM) Free Cash Flow $-10.11m
Cash position $1.16m
EPS (TTM) EPS $-10.35
P/S forward 34.88
EV/Sales forward 25.41
Short interest 3.36%
Show more

Is Organovo Holdings, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Organovo Holdings, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Organovo Holdings, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Organovo Holdings, Inc.:

Hold
100%

Financial data from Organovo Holdings, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.12 0.12
50% 50%
100%
- Direct Costs 0.28 0.28
4% 4%
233%
-0.16 -0.16
433% 433%
-133%
- Selling and Administrative Expenses 7.12 7.12
27% 27%
5,933%
- Research and Development Expense 5 5
48% 48%
4,167%
-12 -12
37% 37%
-10,233%
- Depreciation and Amortization 0.28 0.28
4% 4%
233%
EBIT (Operating Income) EBIT -13 -13
36% 36%
-10,465%
Net Profit -12 -12
35% 35%
-10,325%

In millions USD.

Don't miss a Thing! We will send you all news about Organovo Holdings, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organovo Holdings, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today reported preliminary unaudited cash for the fiscal year ending March 31, 2025, and net cash utilization results for the fiscal fourth quarter of 2025....
Neutral
GlobeNewsWire
7 days ago
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today provided a business update.
Neutral
GlobeNewsWire
9 days ago
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) (“Lilly”).   The transa...
More Organovo Holdings, Inc. News

Company Profile

Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Keith Murphy
Employees 20
Founded 2012
Website www.organovo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today